FODMAP

Although two restrictive diets and medical treatment all reduced the severity of symptoms in irritable bowel syndrome, the effect was greater with diets, suggesting their potential as first-line treatment, according to researchers.

Patients with irritable bowel syndrome who tested positive for fructan or fructose malabsorption via hydrogen breath testing had nearly two times higher odds of testing positive for the other carbohydrate, according to study results.

Treating patients with irritable bowel syndrome can be a challenge for health care providers, as patients with suspected IBS often report a lengthy list of visceral and somatic symptoms that can overwhelm a busy provider.

Results from a 2023 nationwide survey published in Gastroenterology estimated the prevalence of Rome IV irritable bowel syndrome in the U.S. climbing to 6.1% — higher than previous reports of 4.7% to 5.3%.

Nearly 7.5 million Americans are expected to reach their holiday destinations by plane this year — a daunting task for most individuals but even more challenging for those with gastrointestinal disorders.

In this podcast episode, Kate Scarlata, MPH, RDN, discusses how to help patients avoid over restricting their diets, the use of digital therapeutic tools in dietetics and more.

In this podcast episode, Tamara Duker Freuman, MS, RD, CDN, discusses how the work of gastroenterologists and dieticians can inform each other, approaching GI conditions as new science emerges and more.

Irritable bowel syndrome is a dysfunction in the communication pathway between the gut and the brain, which contributes to symptoms such as gas, bloating, abdominal pain, diarrhea, constipation and mixed bowel habits.

SAN DIEGO — Two restrictive diets were superior in reducing symptoms compared with optimized medical treatment alone in patients with irritable bowel syndrome, according to results presented at Digestive Disease Week 2022.

According to the International Foundation for Gastrointestinal Disorders, irritable bowel syndrome is estimated to effect 10% to 15% of the population worldwide, making it the most prevalent functional GI disorder.